Skip to main content
. Author manuscript; available in PMC: 2014 Feb 6.
Published in final edited form as: Hypertension. 2012 Jun 4;60(1):71–80. doi: 10.1161/HYPERTENSIONAHA.112.192500

Figure 1.

Figure 1

Effect of epidermal growth factor receptor (EGFR) tyrosine kinase (EGFRtk) inhibition on plasma glucose, body weight, fibrosis, EGFRtk, and endoplasmic reticulum (ER) stress markers in heart from streptozotocin (STZ) mice. A and B, Glucose levels (mg/dL) and body weight (BW) were determined in control, STZ, and STZ+AG1478 groups; n=7. The vertical dashed lines denote the start of infusion of AG1478. ▼, control; ◆, STZ+AG1478; □, STZ. C, Representative histological sections from the heart stained with Sirius-red; bars indicate the quantitative data, n=5. D and E, Representative Western blot analysis and quantitative data for plasminogen activator inhibitor (PAI) 1 and collagen I in heart in all groups, n=4 to 5. F and G, EGFR mRNA levels, n=5 and representative Western blot analysis and quantitative data for phosphorylated EGFR and total EGFR in all groups; n=5. H and I, CHOP mRNA levels, n=5, and CHOP representative Western blot and quantitative data in all groups, n=3. J and K, ATF-4 and ATF-6 mRNA levels, normalized to 18S rRNA, in all of the groups, n=5. *P<0.05 for STZ vs control; #P<0.05 for STZ vs STZ+AG1478; $P<0.05 for STZ+AG1478 vs control.